Rebound bei Affymetrix !

 

hab bei 3,30 einige STücke über xetra abgegriffen, allerdings weniger als 100^^. bleibt interessant, werd auch nachkaufen, die Frage ist nur wann und zu welchem Kurs  

..Email0
Share0Print.....RELATED QUOTES..Symbol Price Change
AFFX 4.32 +0.52

......

Shares of Affymetrix Inc. climbed Thursday, a day after the genetic testing instrument maker turned in a second-quarter performance that topped Wall Street expectations.

THE SPARK: The Santa Clara, Calif., company said Wednesday it lost $6.1 million, or 9 cents per share, in the quarter. Excluding one-time items, it posted profit of 4 cents per share, while revenue grew 20 percent to $79.5 million.

Analysts expected, on average, that Affymetrix would break even on $78.2 million in revenue, according to FactSet.

THE BIG PICTURE: Affymetrix makes technology that helps analyze biological systems at the cell, protein and gene levels. It provides kits for molecular biology applications like DNA sequencing and protein analysis.

THE ANALYSIS: Cowen and Co. analyst Doug Schenkel said in a research note he saw "promising signs of improved stability and execution discipline" in the company's performance.

"While the core Gene Expression business continues to decline significantly, (Affymetrix's) key growth drivers remain intact," Schenkel wrote. Still, he said that he needs to see more consistency from the company, whose shares he rates "Market Perform."

SHARE ACTION: Up 12 percent, or 45 cents, to $4.25 in late trading Thursday. The stock has traded between $2.96 and $5.26 over the past year

MFG
Chali  

SANTA CLARA, Calif.--(BUSINESS WIRE)--

Affymetrix, Inc. (AFFX) announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomics Microarray Consortium conference being held in Chicago this week.

Despite the growing need of cancer researchers and clinicians, obtaining high-quality, whole-genome copy number data from degraded FFPE-derived tumor DNA has remained extremely challenging due to the limitations of current methods such as FISH, array CGH, and next-generation sequencing technologies.

The new OncoScan FFPE Assay Kit, utilizing Affymetrix’ unique Molecular Inversion Probe (MIP) technology, is capable of analyzing small amounts of highly degraded DNA from FFPE samples quickly and affordably, providing a significant step forward in solid tumor cancer analysis.

This new product provides whole-genome copy number data with specifically enhanced high resolution in approximately 900 known cancer genes, loss of heterozygozity (LOH) across the whole genome as well as clinically relevant somatic mutation data − all from a single assay. An updated version of BioDiscovery’s Nexus software, OncoScan™ Nexus Express Software, enables copy number calls for hundreds of samples in minutes and will be included with the product.

The new kit was successfully tested earlier this year in leading cancer research institutes, including M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and ARUP Laboratories.

“We performed testing of the new OncoScan™ FFPE Assay Kit at ARUP on multiple solid tumor tissues, including melanoma, glioma, breast carcinoma, and liposarcoma,” commented Sarah South, Medical Director at ARUP Laboratories. “We used the recommended 80 ng of DNA from FFPE and were able to complete the assay over a 48-hour period. We were able to detect FISH-confirmed aberrations in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting that OncoScan FFPE Assay Kit can be considered a viable higher resolution and higher specificity alternative to FISH testing for confirmation of cancer gene aberrations in solid tumor tissue. Because OncoScan FFPE Assay Kit has whole-genome resolution, we also obtained valuable incremental copy number aberrations in these samples.”

Professor Torsten Pietsch, MD, PhD, Institute of Neuropathology, University of Bonn observed that based on his experience with a large cohort of FFPE brain tumor samples, “We believe that the OncoScan FFPE Assay Kit is a robust platform for the rapid discovery and validation of novel prognostic copy number signatures, that may also be useful in a clinical setting for the detection of specific gains in tumors as markers for patient stratification.”

“The significance of copy number aberrations is being established in an ever increasing number of genes; however, few studies have realized this potential for solid tumors because of the challenges of working with low-input FFPE samples,” said Andy Last, Executive Vice President of the Genetic Analysis and Clinical Applications Business Unit at Affymetrix. “OncoScan FFPE Assay Kit is a game changer for cancer laboratories that want to quickly and affordably analyze hundreds of degraded FFPE samples to correlate copy number aberrations with outcomes data. In addition, the ability to detect a range of clinically relevant somatic mutations adds even more value to the assay and analysis.”

The technology has previously been made available via the OncoScan™ FFPE Express 2.0 Service from the Affymetrix Research Services Laboratory and has demonstrated an unparalleled success rate, with more than 70 publications in the last two years. The platform enables detection in highly degraded samples unlocking a wealth of stored information in FFPE archives of ten years and older.

Affymetrix is accepting orders immediately and will begin shipping the product as early as September this year.

PLEASE NOTE: Affymetrix®, the Affymetrix logo, and OncoScan™ trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

Products mentioned in this release are for research use only. Not for diagnostic procedures.

SOURCE: Affymetrix, Inc

MFG
Chali  

Today I'll offer a stock idea in the genetic research field. Santa Clara, California,-based Affymetrix (AFFX), a leading player and pioneer in developing and selling genomics research analysis equipment, is poised to be an excellent turnaround story. After years of accumulated debt and declining revenues, the company has finally undertaken a long-term strategy for returning to profitability.

It appears to me that Affymetrix is incredibly cheap in light of its turnaround initiative as its restructuring and debt reduction efforts should boost its financial performance significantly going forward. It seems the company is moving in the right direction. I believe the stock could turn out to be a multi-bagger if the turnaround initiative becomes successful, which looks like a strong possibility right now.

Affymetrix: At A Glance

Affymetrix provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level primarily in the United States, Europe, Latin America and Asia. In June 2012, Affymetrix acquired eBioscience for $315 million in cash, a company that specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses.

Last year Affymetrix reorganized its business in the following four business units: Expression, Genetic Analysis and Clinical Applications, Life Science Reagents and Corporate. These four business units represent one reportable operating segment for the company, Affymetrix Core, apart from eBioscience, the other reportable operating segment.

Background

Affymetrix's main product line has been the GeneChip microarray platform, an instrument system in genomics research. Affymetrix was the first company to develop the GeneChip microarray platform, which is widely used in many research institutions as an essential part of genetic analysis. GeneChip's components include disposable probe arrays, reagents, a scanner and software. It offers an integrated solution for gene expression and genotyping. Affymetrix sells the reusable portions of this platform, including the reagents and the analysis instrument, at low margins but sells the one-time-use consumable probe arrays at a high margin.

Apart from GeneChip, the company offers two other instrument systems, namely GeneTitan and GeneAtlas. GeneTitan consists of the GeneTitan tool, Axiom array plates/custom arrays and gene expression array plates. The GeneTitan platform provides an automated solution for monitoring gene expression and genome-wide single nucleotide polymorphisms (SNPS, in short) genotyping. Affymetrix's GeneAtlas platform consists of the GeneAtlas microarray system and gene expression array plates.

After Affymetrix pioneered the GeneChip system, many biotech companies expanded their product lines to include similar systems with the same functionality. As a result, Affymetrix's market share and profitability started to decline. However, to regain market share and return to profitability, Affymetrix management is transforming the company from one that is highly dependent on its GeneChip product line to one with diversified revenue streams with a broad reach in the field of translational medicine, molecular diagnostics and agricultural biotechnology. Acquisition of eBioscience was the first step in the transformation process.

Affymetrix's Turnaround Initiative

Affymetrix management has divided its turnaround initiative into three phases. In Phase I (2011-2012), the company acquired eBioscience and released Cytoscan cytogenetics arrays for genotyping and gene expression applications. Affymetrix reckons cytogenetics is a promising area for expansion, representing market opportunities of roughly $200 million.

In Phase II (2013-2014), Affymetrix management will focus on establishing the company as a key provider of molecular diagnostics products and building its presence in the applied genomics market, particularly in agrigenomics. Management will be looking to commercialize newer product lines, which include CytoScan, Axiom and QuantiGene lines, as well as eBioscience products.

In this phase Affymetrix management is aiming at ensuring sustained profitability by strengthening its balance sheet. For achieving this management is implementing a corporate restructuring program, which is expected to result in annualized savings of approximately $25 million. Furthermore, the company has initiated a cost reduction program in the form of reducing headcount. During the three months ended March 31, 2013, approximately 100 employees were notified of their involuntary termination.

Finally, in Phase III (2015-2016), Affymetrix will be looking for some strategic acquisitions in order to boost the top line significantly. A robust balance sheet will help the company in doing so, Affymetrix management expects.

Affymetrix's Microarray Solutions to Boost Market Share

Affymetrix is evolving into a provider of scalable and innovative genomic analysis tools for scientific discovery, exploration, validation and genetic testing. The company acquired Panomics, USB and Anatrace for high-throughput, mid- to low-plex assays and high-quality, cost-effective molecular biology reagents and biochemicals that enable a complete solution for genome-wide to single-gene analysis.

Affymetrix offers microarray solutions that include all necessary components for a successful microarray experiment, from arrays and reagents to instruments and software. Furthermore, the company provides a complete range of solutions that addresses diverse research needs, from RNA to DNA analysis, a few to thousands of samples, and complete genome-wide analysis.

The company recently announced that it will add a new genotyping format into its existing Axiom genotyping platform. I believe that the format, known as Axiom 384HT, will act as a positive catalyst to boost the company's applied genomics market share. This is a breakthrough innovation that will lead to a cost-effective, high-throughput format for genotyping in which 384 samples are simultaneously processed with 384 discrete microarrays in a microplate format analyzing up to 50,000 SNPs per sample. Moreover, it will address both the human and agrigenomics fields of study using population-optimized or application-focused content.

Limagrain, a French agricultural cooperative and the fourth largest seed company in the world, has already adopted the Axiom 384HT format for routine genotyping of a number of plants. I expect that more such agricultural farms will adopt Axiom 384HT in the near future.

Affymetrix Expanding Into Cancer Research

Affymetrix believes that cancer research could provide market opportunities of approximately $500 million. Affymetrix has been providing OncoScan as a service for about two years now, and the company recently launched the OncoScan platform to facilitate commercial availability of the product version of OncoScan. The platform will not only allow customers to analyze samples at their own labs, but also help them to analyze whole-genome copy number changes. Moreover, OncoScan will help users to analyze a wide range of clinically relevant somatic mutations in tumor biopsy samples.

In April this year, Affymetrix and BioDiscovery announced the availability of Nexus for OncoScan Software for the analysis of whole genome copy number data generated from formalin-fixed, paraffin-embedded (FFPE, in short) solid tumor samples using the OncoScan FFPE Express 2.0 Service. These initiatives will help the company gain market share in cancer research.

Affymetrix's Competitive Advantage

To guard against strong competitors delivering similar products, Affymetrix maintains various collaborative relationships with key technology providers and research organizations. Affymetrix has technology collaborations with a number of instrumentation and reagent companies including Beckman Coulter, Life Technologies Corporation, Luminex Corporation and Qiagen GmbH.

In March this year, Affymetrix entered into a partnership with Aqua Gen and the Center for Integrative Genomics (CIGENE) at the Norwegian University of Life Sciences to genotype more than 900,000 markers per sample from the Atlantic salmon to implement genomic selection and enhance the salmon breeding program at Aqua Gen.

Affymetrix also entered in a joint research program with UK Biobank in March to carry on a long-term epidemiological study investigating complex human diseases affecting public health. The aim of this large-scale project is to improve the diagnosis and treatment of diseases such as cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia.

More Positive Catalysts for Affymetrix Stock

Affymetrix exited the second quarter with a strong financial position with total cash and cash equivalents of $44.1 million. After paying down 25% of its debt over the last year, Affymetrix has now $22.8 million in net debt excluding its convertible debt. With Affymetrix's current debt position at a very manageable level, it's a strong possibility right now that the company will look into refinancing its remaining debt to reduce interest burden.
The company continues to aggressively grow both segments of its Genetic Analysis business, genotyping and clinical arrays. I expect that Affymetrix's clinical diagnostic business will grow in double digits in 2013, driven by its cytogenetics program and increased traction of its Axiom genotyping platform.
Affymetrix recently implemented a broad and an aggressive marketing campaign for its Human Transcriptome Array or HTA, which has the potential to stabilize its Expression business. HTA is a complement to RNA sequencing as it addresses some of the limitations of that application. This HTA application is also an excellent complement to the company's newly launched OncoScan assay, which measures copy number and somatic mutations in the same clinical sample type.

Affymetrix: Valuation and Short-Term Target

Affymetrix's EBITDA for the second quarter of 2013 was $13.6 million or 17% of sales, and year-to-date EBITDA is more than $24 million or 15% of sales. Since Affymetrix is still a loss-making entity, it is not possible to value the company using a P/E multiple. In terms of Price to Book multiple for the last quarter, the stock is currently trading around 1.3x, well below the industry average of 3.71x.

AFFX Price / Book Value data by YCharts

With respect to Price to Book, Affymetrix is trading at a significant discount relative to its peers offering similar product lines, such as Agilent Technologies (A), Illumina (ILMN), Pacific Biosciences of California (PACB), Abiomed (ABMD) and Life Technologies (LIFE). However, Affymetrix not being profitable yet, I would assign a Price to Book multiple of only 2x (on a Book Value per Share of $3.626) for the company, which leads to my short-term target price of $7.25 for the stock. That's a 45% upside from the current price of $5.00. But in the long-term, as I said above, the stock could emerge as a potential multi-bagger.

Should You Consider Buying Affymetrix at the Current Price?

Despite competition, Affymetrix is a leading player in genetic engineering. I feel the company is transitioning to become a complete player in genetic research. Affymetrix's turnaround initiatives will help the company cover a wide array of segments, starting from instrument systems in genomics research to applied genomics and agrigenomics to cytogenetics. With so many sources of revenue, it's hard to believe the company won't succeed. Furthermore, as an emerging player in cancer research, its revenue is expected to grow by 20% y-o-y.

Don't forget, if you buy Affymetrix, you're actually buying a unique genetic engineering business that covers almost every segment in the field. And when it's a turnaround story, your chance of making money increases manifold. I believe the company will return to profit within FY2014, much earlier than Phase III is complete. The company already posted an EPS of $0.04 for Q2, 2013. Another quarter of positive EPS could act as a tremendous trigger for the stock. I think the eBioscience acquisition was the real catalyst for the company, which Mr. Market failed to understand initially.

I would recommend buying the stock at the current price, as I feel Mr. Market has finally understood the growth potential. I expect my short-term target of $7.25 would play out within 2013.

Potential Risks

The biggest issue the company has is its North America growth rate. It's a pretty difficult situation with the sequestration and price pressure. Although the company is seeing good growth rates in Europe and Asia, it's struggling in North America.
The company is heavily reliant on orders from research institutions to generate revenue. As a result, fluctuations in the research funding for these institutions, a large percentage of which come from NIH grants, would negatively impact Affymetrix's revenue growth.
Affymetrix's GeneChip probe arrays are created using publicly available genetic sequencing information, which is updated daily and changed frequently due to new discoveries in the field. This exposes some of Affymetrix's products, the GeneChip microarray platform in particular, to the risk of becoming obsolete if the company fails to update them.
Conclusion

Affymetrix's strategic acquisitions and collaborations, new product launches and shift of focus toward diversified revenue streams are expected to propel future top line growth. The company is aggressively cutting expenses for expanding margins and boosting profitability. It's undoubtedly an excellent turnaround story worth looking into.

MFG
Chali  

http://www.thestreet.com/story/12016219/1/...stock-upgraded-affx.html

 

http://www.zacks.com/stock/news/107195/...nue-for-affymetrix-inc-affx

 

http://www.affymetrix.com/estore/

http://www.affymetrix.com/about_affymetrix/media/events.affx

http://finance.yahoo.com/news/...urnaround-2q-earnings-161502368.html

http://www.nasdaq.com/article/...nd-2q-earnings-analyst-blog-cm265649

http://finance.yahoo.com/news/...s-oncoscan-ffpe-assay-103000566.html

http://uk.finance.yahoo.com/news/...m-384ht-genotyping-103000744.html

 

http://finance.yahoo.com/news/...inches-close-ceptaris-150005978.html

 

http://eon.businesswire.com/news/eon/...t-Cancer-Index-molecular-test

 

Time to Buy the Health Care Sector? Senior Managing Director Ross Muken Surveys the Landscape

http://finance.yahoo.com/news/...uy-health-care-sector-170600013.html

 

http://finance.yahoo.com/news/...-posting-first-profit-153017048.html

 

Was genau haben die hier in der Pipeline? Worin besteht die Chance?  

Affymetrix ist eigentlich gar kein biotechwert,musst du wissen,es handelt sich eher um Medizintechnik,genauer um Microarray-Diagnostiksystems für klinische Diagnostik. Affymetrix wurde mir als Multibagger turnaroundstory empfohlen,aber ich bin mit 60% Plus vor einigen Tagen ausgestiegen,um Lpath weiter aufzustocken. Langfristig sehe ich hier ca. 500 - 1000% Potential ,vielleicht mehr,die Gewinnschwelle ist erreicht und die Hauptkonkurrenten Agilent (15 MRD) und Illumina (12 MRD) sind viel höher bewertet,eben so hoch wie Affymetrix vor 13 Jahren schon bei 150 Dollar stand,jetzt bei 6 Dollar mit 440 Mio Börsenwert ! Das ist im angesprochenen Peer Group Vergleich einfach viel zu wenig ! Die aktie steigt fast jeden Tag zwischen 2 und 4 Prozent,also eher gemächlich ....

Übrigens: Für kurzfristige sehr gute Gewinne empfehle ich Cardiome Pharma !!! Ich bin seit 2 Dollar dabei ,aktuel bei 3,77 Dollar,gestern plus 16% und vorvorgestern plus 25% ,es geht aufwärts,aus gutem Grund:

http://www.ariva.de/forum/Cardiome-Pharma-in-der-analyse-412636

MFG
Chali  

Affymetrix (AFFX: Nasdaq) By Maxim Group ($6.14, Sept. 30, 2013) We reiterate our Buy rating on Affymetrix and are raising our estimates and target price to $8 from $6. Despite continued weakness of Affymetrix's (ticker: AFFX) gene expression business, we ...

Krieg den komletten Artikel nicht rein ....  

Aber noch ist alles im Lot. Das man 4 Werte kauft und alle 4 klettern gleich los, wäre wohl etwas ...  

Heute marschieren alle deine 4 Werte ins Plus,während die PB Longs schin wieder darben ......

Hm ?  

Und es ist heute ein cooles Gefühl, so gekauft zu haben. Danke, Chalif.  

Global genetic devices maker, Affymetrix Inc. (AFFX) posted adjusted earnings per share of 5 cents in the third quarter of 2013, surpassing the Zacks Consensus Estimate of 2 cents and rebounding from the year-ago adjusted loss of 3 cents. Reported net loss in the quarter was $4.2 million or 6 cents per share, narrower than the year-ago net loss of $17.9 million or 25 cents.

Revenues inched up 0.9% to $80.4 million, beating the Zacks Consensus Estimate of $79 million. Product revenues improved 2.9% to $74.8 million, while Service and other revenues dropped 18.8% to $5.6 million in the reported quarter.

Product revenues included consumable sales of $52.1 million, up 3.2%, and instrument sales of $2.8 million, down 39.1% from the prior-year quarter. Revenues from the acquired eBioscience unit increased 13.1% to 19.9 million in the quarter.

Gross margin surged 300 basis points (bps) to 55% from 52% in the third quarter of 2012. However, on an adjusted basis, gross margin increased 100 bps to 61%.

Selling, general and administrative (SG&A) expenses decreased 7.2% to $33.7 million, and research and development (R&D) expenses fell 30.3% to about $11.5 million. As a result, AFFX’s reported operating expenses were down 14.6% to $45.1 million.

On an adjusted basis, operating expenses declined 8.9% to $41.9 million, mainly due to reduced headcount and lower variable compensation expenses following the company’s restructuring initiatives. Moreover, one-time acquisition- and integration-related costs incurred in 2012 led to the year-over-year fall in expenses.

Financial Condition

Affymetrix ended the third quarter of 2013 with cash and cash equivalents of $50.2 million, almost two-fold increase from $25.7 million at the end of 2012. On an encouraging note, the company generated roughly $10.5 million in cash flow from operations due to higher revenues and controlled operating expenses, combined with efficient working capital management. In addition, AFFX reduced senior-secured debt by almost 45% since June 2012.

Recent Developments

In October, Affymetrix divested its Anatrace product line to StoneCalibre. The company used the proceeds as well as cash-on-hand to reduce outstanding senior-secured debt.

In the same month, AFFX also refinanced $48 million of its remaining senior-secured debt on revised terms including lower interest rate margins. As of Oct 25, 2013, the company’s cash-on-hand exceeded the principal amount of its senior-secured debt.

Our Take

This was the second consecutive quarter in which Affymetrix was able to maintain its earnings momentum. The company had been posting losses since the first quarter of 2011, until it reported earnings in the last quarter. AFFX’s strategic restructuring plans are finally paying off as demonstrated by its bottom-line growth.

We believe that Affymetrix is ready for a turn around and the worst days are over for the company. In the face of declining demand for Affymetrix’s flagship GeneChip Expression products, management strategy to transform AFFX into a company with a broad reach in the high-growth markets for translational medicine, molecular diagnostics and applied markets is indeed encouraging. Additionally, the company’s restructuring and debt reduction efforts should boost margins and profitability going forward.

However, we are cognizant regarding AFFX’s flattish top-line growth. A tight U.S. academic funding environment and increasing pricing pressure along with operational hazards in Japan remain potential headwinds. Moreover, declining R&D spending raises concerns over future product development and growth for the company.

Currently, Affymetrix has a Zacks Rank #4 (Sell). While we prefer to avoid AFFX at present, companies like Isis Pharmaceuticals, Inc. (ISIS), AMAG Pharmaceuticals, Inc. (AMAG) and Actelion Ltd. (ALIOF), all carrying a Zacks Rank #1 (Strong Buy), are expected to do well in the Medical-Biomed/Gene industry

MFG
Chali  

die 6€ genommmen werden,wären die hochs aus 2009 /2010 und 2011 geknackt und der weg nach oben frei !! Das könnte schon diese woche klappen,je nach dem wie sich eBioscience und insbesondere die neuen Produkte von eBioscience entwickeln und natürlich die Verkaufszahlen der neuen Oncosec Software sind entscheident für weitere Kurszuwächse,die im best case meiner Meinung nach noch 400% betragen,erst bei einem Kurs von 30 Dollar sollte man ernsthaft an Verkäufe und Gewinn,itnahmen denken !

Viel Erfolg !!

MFG
Chali  

The U.S. FDA authorized for marketing the Affymetrix CytoScan Dx Assay, which can detect chromosomal variations that may be responsible for a child's developmental delay or intellectual disability. Based on a blood sample, the test can analyze the entire genome at one time and detect large and small chromosomal changes.

Hat den Kurs aber nicht beeinflusst. Vielleicht waren die Cowboys schon im WE. Mal sehen, ob nächste Woche die Amis was draus machen!
 

Pre-Market Quote and Chart$10.01* 0.75 8.1% Get AFFX Alerts

 

geht die Reise aufwärts noch?
Gefällt mir die letzte Zeit sehr gut!